Drug Liver Toxicity Risk Could Be Monitored In Extended Phase III - Temple

Phase III studies could be extended to monitor the hepatotoxicity risk of drugs in development, FDA Office of Medical Policy Director Robert Temple, MD, suggested during a Feb. 13 workshop on liver toxicity.